GenEditBio is at the forefront of advancing healthcare by developing innovative genome editing therapies aimed at treating rare diseases, cancer, and other critical illnesses.
Location: China
Investors 2
| Date | Name | Website |
| 03.09.2025 | Gobi Partn... | gobi.vc |
| 20.01.2024 | Qiming Ven... | qimingvc.c... |
Mentions in press and media 6
| Date | Title | Description |
| 05.01.2026 | GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy | HONG KONG, Jan. 5, 2026 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. Food and Drug Administration (FDA) h... |
| 24.11.2025 | GenEditBio and ToolGen Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics | Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology Pursues a "once-and-done" treatment paradigm for diseases with high unmet medical needs SEOUL,... |
| 24.11.2025 | ToolGen and GenEditBio Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics | Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology Pursues a "once-and-done" treatment paradigm for diseases with high unmet medical needs SEOUL,... |
| 08.06.2025 | GenEditBio and Newborn Town: Pioneering Innovations in Hong Kong's Biotechnology and Entertainment Sectors | In the bustling heart of Hong Kong, two companies are making waves in their respective fields. GenEditBio, a biotechnology start-up, is pushing the boundaries of genetic medicine. Meanwhile, Newborn Town, a social entertainment giant, is re... |
| 06.06.2025 | GenEditBio Announces First Patient Dosed in Investigator-Initiated Trial of GEB‑101, World's First In Vivo CRISPR-Cas Ribonucleoprotein-Based Genome Editing Investigational Therapy for TGFBI Corneal D... | HONG KONG, BEIJING and BOSTON, June 6, 2025 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology start-up company focusing on genome editing therapeutic solutions through the discovery of novel and pre... |
| - | GenEditBio | “GenEditBio” |